Cardiovascular

Nebivolol hydrochloride

Brand: Nebilet®

PBAC's latest decision on Nebivolol hydrochloride: Recommended with restriction (2009). Considered for treatment of stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older (TGA indication).

PBAC outcome

Recommended with restriction

Authority Required (STREAMLINED)

ICER (AUD/QALY)

Cost-min

cost-minimisation analysis

Submissions

first 2009

Submissions

2009 → 2009

Eligible population

patients stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II receptor antagonist (if tolerated)

Therapy area: Cardiovascular
Line of therapy: Later-line
Evidence base: RCT
Primary endpoint: other
Key trials: Patrianakos 2005, Lombardo 2006, Marazzi 2007, SENIORS ECHO, Carvediol ANZ
Comparator: carvedilol, bisoprolol and metoprolol
Economic model: Cost-minimisation
Budget impact: $-5000000
ICER note: Cost minimisation analysis presented; no ICER calculated as equi-effectiveness was assumed

Open on full dashboard →